Williamstown, MA -- (SBWIRE) -- 03/09/2012 -- GBI Research, the leading business intelligence provider, has released its latest research "Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma". The report provides in-depth analysis of drivers and barriers that impact the global Hospital Acquired Bacterial Infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
View Full Report Details and Table of Contents
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The global hospital acquired bacterial infections market mainly comprises of four indications which are Urinary Tract Infections (UTI), pneumonia, Bloodstream Infections (BSI) and Surgical Site Infections (SSI). The total market of HABI is dependent on the major infections which are mainly caused by multi-drug resistant bacteria. Increasing human resistance to anti-bacterials leads to a need for advanced therapies to treat bacterial infections. Patent expiry of major antibacterials like Zyvox, Invanz, Tobi and Levaquin is set to erode the HABI market. This decline in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterial R&D due to low Return on Investment (RoI). The lifespan of antibacterials is frequently limited due to the development of drug resistance. Big Pharma prefers acquiring small and niche pharmaceutical companies to widen their antibacterial pipeline portfolio.
The HABI market will show decline in the forecast period. The market is forecast to decline at a negative CAGR of 3.4% in the forecast period 2010-2017. Decline in the HABI market will be due to two main reasons. Firstly, there is resistance developed against antibacterials which makes existing antibacterials obsolete in some conditions. Secondly, there is an increase in hospital surveillance which leads to a decline in HABIs. Based on CDC data, 20% to 30% of hospital acquired infections can be prevented by infection control programs. There is formation of government bodies which are making it mandatory for hospitals to cut down on the spread of infections in the healthcare setup.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth
- Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccines
- Big Pharma Mega-Mergers 1995-2014
- Drug Delivery Technologies: Players, products & prospects to 2018
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
- M&A trends in Pharma
- Drug and Device Combination (2009 - 2014)
- Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation
- Pharmaceutical Licensing Overview